by Truveta staff | Dec 6, 2024 | News
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta News | Nov 20, 2024 | News
We are excited to share that our platform Truveta Studio and Truveta Data have earned certified status by HITRUST for information security. This achievement places Truveta in an elite group of organizations worldwide that have earned this certification. HITRUST r2...
by Truveta News | Nov 14, 2024 | News
Truveta Data, the most complete, timely, and clean electronic health record (EHR) data, now includes more than 120 million de-identified patients – more than one-third of the U.S. population – empowering researchers to study patients representative of the diversity of...
